Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques.

bioRxiv : the preprint server for biology Pub Date : 2025-04-01 DOI:10.1101/2025.03.20.644395

Jessica Coppola, Mara Parren, Raiza Bastidas, Karen Saye-Francisco, Jacqueline Malvin, Joseph G Jardine, Roxanne M Gilbride, Sohita Ojha, Shana Feltham, David Morrow, Aaron Barber-Axthelm, Rachele Bochart, Randy Fast, Kelli Oswald, Rebecca Shoemaker, Jeffrey D Lifson, Louis J Picker, Dennis R Burton, Scott G Hansen

{"title":"Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques.","authors":"Jessica Coppola, Mara Parren, Raiza Bastidas, Karen Saye-Francisco, Jacqueline Malvin, Joseph G Jardine, Roxanne M Gilbride, Sohita Ojha, Shana Feltham, David Morrow, Aaron Barber-Axthelm, Rachele Bochart, Randy Fast, Kelli Oswald, Rebecca Shoemaker, Jeffrey D Lifson, Louis J Picker, Dennis R Burton, Scott G Hansen","doi":"10.1101/2025.03.20.644395","DOIUrl":null,"url":null,"abstract":"<p><p>A vaccine is widely regarded as necessary for the control of the HIV pandemic and eventual eradication of AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have both been shown capable of vaccine protection against the simian counterpart of HIV, SIV, in rhesus macaques. Here we provide preliminary evidence that combining these orthogonal antiviral mechanisms can provide increased protection against SIV challenge such that replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced in the presence of passively administered incompletely protective levels of neutralizing antibody. The report invites studies involving larger cohorts of macaques and alternate routes of providing neutralizing antibody.</p>","PeriodicalId":519960,"journal":{"name":"bioRxiv : the preprint server for biology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974736/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv : the preprint server for biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2025.03.20.644395","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

A vaccine is widely regarded as necessary for the control of the HIV pandemic and eventual eradication of AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have both been shown capable of vaccine protection against the simian counterpart of HIV, SIV, in rhesus macaques. Here we provide preliminary evidence that combining these orthogonal antiviral mechanisms can provide increased protection against SIV challenge such that replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced in the presence of passively administered incompletely protective levels of neutralizing antibody. The report invites studies involving larger cohorts of macaques and alternate routes of providing neutralizing antibody.

查看原文本刊更多论文

恒河巨细胞病毒/SIV疫苗与中和抗体联合免疫恒河猴。

疫苗被广泛认为是控制艾滋病毒流行和最终根除艾滋病所必需的。在恒河猴中，中和抗体和mhc - e限制性CD8+ T细胞都显示出能够对艾滋病毒的类人猿对应物SIV提供疫苗保护。在这里，我们提供了初步证据，表明结合这些正交的抗病毒机制可以增强对SIV攻击的保护，例如，在被动给予不完全保护水平的中和抗体的情况下，接种恒河巨细胞病毒（RhCMV/SIV）疫苗后观察到的复制停滞得到增强。该报告邀请研究涉及更大的猕猴群体和提供中和抗体的替代途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

bioRxiv : the preprint server for biology

自引率

0.00%

发文量